Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Offering SPR-BLI Services - Proteins provided for free!
Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Mouse
3B10
IHC
Immunohistochemical analysis of paraffin-embedded human stomach tissue labeling Claudin-18.2 with HCB-Y126 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. Membranous staining on human gastric epithelial cells is observed. Counter stained with Hematoxylin. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded human lung tissue labeling Claudin-18.2 with HCB-Y126 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. The staining in the lung tissue sample was negative. Counter stained with Hematoxylin. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded human cancer tissue labeling Claudin-18.2 with HCB-Y126 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. Membranous staining on tumor cells is observed. Counter stained with Hematoxylin. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(EUR) : €510.00
Price(EUR) : €2020.00
ACROBiosystems offers a wide selection of Matrigengel basement membrane extracts. Different versions – including phenol red-free, high concentration, iPSC culturing, organoid culturing – are all available for your specific needs to support 3D cell culture!
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 1 Clinical | Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms | Details |
IBI-345 | IBI-345 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
CMG-901(Connaught Biomedical Technology) | CMG-901 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
QLS-31905 | QLS-31905 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | Details |
NBL-015 | NBL-015 | Phase 1 Clinical | Shanghai Xinshi Biological Medicine Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms | Details |
BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
DR-30303 | DR30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
IBI-389 | IBI-389 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
M-108 | M108; M-108 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | Details |
Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma | Details |
Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Neoplasms | Details |
IBI-360 | IBI-360 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
LB-1904 | LB-1904 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Stomach Neoplasms | Details |
KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Stomach Neoplasms; Carcinoma, Pancreatic Ductal | Details |
CT-041 | CT041 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
IMC-002(Suzhou Immunofoco) | IMC-002 | Phase 1 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
LY-011(Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
LM-302 | LM-302; TPX-4589 | Phase 2 Clinical | Eli Lilly Trading (Shanghai) Co Ltd | Solid tumours | Details |
CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | Zhongshan City People'S Hospital | Stomach Neoplasms | Details |
HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
ZL-1211 | ZL-1211 | Phase 2 Clinical | Zai Lab (Shanghai) Co Ltd | Solid tumours | Details |
BA-1105 | BA-1105 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
PM-3023 | PM-3023 | Phase 1 Clinical | Biotheus Inc | Solid tumours | Details |
SOT-102 | SOT102; SO-N102; SOT-102 | Phase 2 Clinical | Sotio Biotech AG | Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms | Details |
124I-18B10 | 124-I-18-B-10; 124I-18B10 | Clinical | Transcenta Holding Ltd, Beijing Cancer Hospital | Gastrointestinal Neoplasms | Details |
TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
JS-012 | JS-012 | Phase 1 Clinical | Solid tumours | Details | |
BNT-141 | BNT-141 | Phase 2 Clinical | Biontech Se | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Esophageal adenocarcinoma; Neoplasm Metastasis; Adenocarcinoma | Details |
PM-1032 | PM1032; PM-1032 | Phase 1 Clinical | Biotheus Inc, Shanghai Genechem Co Ltd | Neoplasms | Details |
KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
JS-107 | JS-107 | Phase 1 Clinical | Solid tumours; Pancreatic Neoplasms; Neoplasms | Details | |
RC-118 | YH005 ADC; RC-118 | Phase 2 Clinical | RemeGen Co Ltd, Beijing Biocytogen Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
PT-886 | PT-886 | Phase 1 Clinical | Phanes Therapeutics Inc | Stomach Neoplasms; Pancreatic Neoplasms | Details |
IM-92 | IM-92 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
Zolbetuximab | iMAB-362; GC-182 | Phase 3 Clinical | Ganymed | Lymphangioma, Cystic; Solid tumours; Pain; Stomach Neoplasms; Esophageal Neoplasms; Gastrointestinal Diseases; Pancreatic Neoplasms; Adenocarcinoma | Details |
Q-1802 | Q-1802 | Phase 1 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Gastrointestinal Neoplasms | Details |
SPX-101 (Sparx Therapeutics) | KY-71113; SX-001; KY71113; SPX-101 | Phase 1 Clinical | Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc | Solid tumours; Stomach Neoplasms | Details |
Osemitamab | MSB-018; TST-001 | Phase 2 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Lung Neoplasms; Gallbladder Neoplasms | Details |
SHR-A-1904 | SHR-A-1904; SHR-A1904 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Pancreatic Neoplasms | Details |
LM-102 | LM-102 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
LB-4330 | Bis-2; LB-4330 | Phase 1 Clinical | L&L Biopharma Co Ltd | Solid tumours | Details |
IBI-343 | IBI-343 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
ATG-022 | ATG-022 | Phase 1 Clinical | Antengene Corporation Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms | Details |
SYSA-1801 | SYSA-1801; SYSA1801; CPO-102; EO-3021 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
TJ-CD4B | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-CD4B/ABL111; TJ-033721 | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis | Details |
SKB-315 | SKB-315; SKB315 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
LCAR-C18S CAR-T cell therapy | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
ASKB-589 | ASKB-589 | Phase 2 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
This web search service is supported by Google Inc.